Table 2 Baseline and follow-up statistics of WHODAS-2.0

From: Magnesium–ibogaine therapy in veterans with traumatic brain injuries

Baseline and follow-up statistics

 

Baseline

Post-MISTIC

Baseline versus post-MISTIC

1 month

Baseline versus 1 month

Fa

PFDR

d

Fa

PFDR

d

WHODAS-2.0 total

30.2 ± 14.7

19.9 ± 16.3

20.38

<0.001

0.74

5.1 ± 8.1

85.85

<0.001

2.20

CAPS-5

31.7 ± 12.5

3.9 ± 4.8

206.14

<0.001

2.30

4.8 ± 7.9

191.77

<0.001

2.54

MADRS

25.6 ± 8.7

2.8 ± 3.3

249.72

<0.001

2.65

3.8 ± 6.0

229.28

<0.001

2.80

HAM-A

20.8 ± 8.5

3.6 ± 3.4

164.24

<0.001

2.06

3.9 ± 4.6

164.24

<0.001

2.13

 

Percentage reporting SI

Percentage reporting SI

X2

PFDR

–

Percentage reporting SI

X2

PFDR

–

SI (MADRS Q10)

47

0

18.26

<0.001

–

7

12.27

<0.001

–

Percentage reduction, response and remission rates

 

Percentage reduction versus baseline

Response rate (%)

Remission rate (%)

Post-MISTIC

1 month

Post-MISTIC

1 month

Post-MISTIC

1 month

CAPS-5

88 ± 15

88 ± 17

97

100

86

86

MADRS

87 ± 23

87 ± 17

100

97

83

83

HAM-A

81 ± 19

81 ± 21

97

93

86

83

  1. All results are presented as mean ± s.d. LME models were used for each comparison with FDR correction applied for determination of significance.
  2. aDegrees of freedom (d.f.) were (1.72) for WHODAS-2.0 and (1.75) for CAPS-5, MADRS and HAM-A.
Back to article page